Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan (NOT-OD-22-178)

Sponsor: National Institutes of Health

Due Date: See announcement.

Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) (PAR-22-213)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) (PAS-22-196)

Sponsor: National Institute on Aging National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) (PAS-22-197)

Sponsor: National Institute on Aging National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Notice of Special Interest: Availability of Administrative Supplements for INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) (NOT-OD-22-137)

Sponsor: National Institutes of Health

Due Date: See announcement.

NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (PAR-22-181)

Sponsor: National Institutes of Health

Award: NINDS intends to commit up to $10 million per fiscal year, approximately 25 awards, dependent on award amounts.

Due Date: Multiple due dates; see announcement.

Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) (PAR-22-184)

Sponsor: National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences

Due Date: Multiple due dates; see announcement.

NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) (PAR-22-142)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional) (PAR-22-145)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) (PAR-22-076)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) (PAR-22-126)

Sponsor: National Institutes of Health

Due Date: Multiple due dates, see announcement.

Focused Technology Research and Development (R01 Clinical Trial Not Allowed) (PAR-22-127)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

NIA Program Project Applications (P01 Clinical Trial Optional) (PAR-22-130)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) (PAR-22-089)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: Multiple due dates; see announcement.

Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) (PAR-22-028)

Sponsor: National Institute of Neurological Disorders and Stroke.

Award: Funds are not awarded; this FOA is to provide investigators with a mechanism to access contract research/medical organizations and subject matter experts within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Due Date: Multiple due dates; see announcement.